Certara, Inc. filings document the public-company record for a Nasdaq-listed provider of biosimulation software and model-informed drug development services. Its 8-K reports include operating and financial results, guidance-related exhibits, material-event disclosures, credit agreement amendments and the completed sale of its global medical writing and related regulatory services business.
Proxy and governance filings describe annual-meeting matters, board composition, executive transitions and stockholder voting procedures. The record also identifies Certara's common stock, capital-structure disclosures and clinical or regulatory disclosures tied to software, services, regulatory science and clinical-development support.
Certara, Inc. reported first quarter 2026 revenue of $106.9 million, up 1% year over year, with 7% growth in software offset by a 4% decline in services. The company swung to a net loss of $8.8 million versus $4.7 million of net income a year earlier, mainly due to higher operating expenses.
Certara closed the sale of its global medical and regulatory writing business to Veristat for $85 million in cash, plus $15 million in escrow and up to $35 million in potential earn-out. Full-year 2026 guidance now calls for $395–$405 million of revenue and adjusted EBITDA margin of about 30%–32%.
Certara, Inc. has entered into a definitive agreement to sell its global Regulatory and Medical Writing business to Veristat. The deal values the business at up to $135 million, including $100 million in cash at closing, subject to customary working capital and other adjustments, plus up to $35 million of contingent earn-out based on future performance. Up to $15 million of the closing payment may be placed in escrow until certain items are satisfied.
The business generated $50 million of revenue and $17 million of adjusted EBITDA in 2025 and includes approximately 220 employees. Certara describes the divestiture as sharpening its focus on Model-Informed Drug Development and Clinical Intelligence, and plans to update its 2026 guidance after the transaction closes, which is expected in the second quarter of 2026, subject to customary conditions.
Wasatch Advisors files an amendment to its Schedule 13G/A reporting beneficial ownership of 5,272,166 shares of Certara Inc. This position represents 3.3% of the outstanding common stock and shows sole voting power over 3,598,349 shares and sole dispositive power over all 5,272,166 shares. The filing is signed by the reporting CEO on 04/06/2026.
Certara Inc Schedule 13G/A amendment shows Wasatch Advisors reports 5,272,166 shares of Common Stock, representing 3.3% of the class. The filing lists 3,598,349 shares with sole voting power and 5,272,166 with sole dispositive power. The filing is signed on 04/06/2026.
Certara, Inc. president and chief commercial officer Leif E. Pedersen reported vesting and settlement of stock awards on April 1, 2026. He exercised restricted stock units and performance stock units to receive 33,167 shares of common stock at an exercise price of $0.00 per share.
He also received a separate award of 14,510 shares of common stock, while 11,611 shares were withheld at $5.70 per share to satisfy tax obligations tied to the RSU and PSU vesting. Following these compensation-related transactions, he directly holds 110,045 shares of Certara common stock.
Certara, Inc. executive Adrian McKemey, President, Drug Development Solutions, exercised 10,849 restricted stock units into common shares on April 1, 2026 at a stated price of $0.00 per share. These RSUs were granted on May 20, 2025 under Certara’s 2020 Incentive Plan.
In connection with vesting, 2,642 common shares valued at $5.70 per share were withheld to satisfy tax obligations, a non-market, tax-withholding disposition exempt under Rule 16b-3. After these transactions, McKemey directly holds 8,207 common shares and 21,698 unvested RSUs scheduled to vest in equal parts on April 1, 2027 and April 1, 2028.
Certara, Inc. SVP and General Counsel Daniel Corcoran exercised restricted stock units into common shares as part of his equity compensation. On April 1, 2026, one-third of a prior RSU grant vested and settled, delivering 10,849 shares of common stock. Of these, 5,751 shares were withheld at $5.70 per share to cover tax obligations, a non-market, tax-withholding disposition. Following these transactions, Corcoran directly held 21,319 shares of Certara common stock. The remaining RSUs from this grant are scheduled to vest and settle in equal parts on April 1, 2027 and April 1, 2028.
Certara, Inc. Chief Financial Officer John E. Gallagher reported a series of equity compensation transactions involving restricted stock units (RSUs), performance stock units (PSUs), and related common stock on April 1, 2026.
He exercised or converted derivative awards into a total of 50,605 shares of common stock and received an additional grant or award of 23,346 common shares. Following these transactions, he directly owned 95,371 shares of Certara common stock.
The filing also shows 25,108 shares of common stock were disposed of to satisfy tax withholding obligations at prices including $5.70 per share, rather than through open-market sales. Footnotes explain that the PSUs and RSUs were granted under Certara’s 2020 Incentive Plan and vested based on multi-year service and performance schedules.
Certara, Inc. executive Robert Aspbury, President, Predictive Tech, reported multiple equity compensation events on April 1, 2026. Previously granted performance stock units and restricted stock units vested and were settled into a total of 33,167 shares of common stock, consistent with the filing’s exercise summary.
To cover related tax obligations, the company withheld 22,411 shares at $5.70 per share under code F, a non‑market, tax-withholding disposition exempt under Rule 16b-3. Aspbury also received a 14,510-share common stock award as compensation and, following these transactions, directly owned 332,442 shares of Certara common stock.
Certara, Inc. Chief Human Resources Officer Rona Anhalt exercised restricted stock units and settled related taxes in shares. She converted 9,764 RSUs into 9,764 shares of common stock on April 1, 2026, as part of a grant made on May 20, 2025 under the 2020 Incentive Plan.
Of these vested shares, 3,062 were withheld to cover tax obligations linked to the RSU vesting, leaving 11,883 shares of common stock held directly after the transactions. One-third of the RSUs vested on April 1, 2026, with the remaining two-thirds scheduled to vest in equal parts on April 1, 2027 and April 1, 2028.